| Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015] | Technology appraisal guidance |
| Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037] | Technology appraisal guidance |
| Etripamil for treating paroxysmal supraventricular tachycardia [TSID12184] | Technology appraisal guidance |
| Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827] | Technology appraisal guidance |
| Extra-vascular implantable cardioverter defibrillator (EVICD) for people with a defibrillator | Interventional procedures guidance |
| Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278] | Technology appraisal guidance |
| Fenebrutinib for treating primary progressive multiple sclerosis [ID6543] | Technology appraisal guidance |
| Fenebrutinib for treating relapsing multiple sclerosis [ID6577] | Technology appraisal guidance |
| Filgotinib for Axial spondyloarthritis [ID12209] | Technology appraisal guidance |
| Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726] | Technology appraisal guidance |
| Galcanezumab for migraine [TSID10663] | Technology appraisal guidance |
| Gambling | Quality standard |
| Gantenerumab for treating early Alzheimer's disease [TSID10668] | Technology appraisal guidance |
| Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 inhibitor and endocrine treatment [ID6576] | Technology appraisal guidance |
| Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072] | Technology appraisal guidance |
| Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208] | Technology appraisal guidance |
| Gosuranemab for treating progressive supranuclear palsy [ID1607] | Technology appraisal guidance |
| Gout | Quality standard |
| Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071] | Technology appraisal guidance |
| Heart valve disease in adults | Quality standard |
| Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129] | Technology appraisal guidance |
| Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747] | Technology appraisal guidance |
| Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720] | Technology appraisal guidance |
| Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579] | Technology appraisal guidance |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies [ID6491] | Technology appraisal guidance |